Summary
Antigenic variation in cancer metastasis was observed in a syngeneic murine tumor system consisting of a low metastatic parental tumor line (derived from a methylcholanthrene-induced DBA/2 T lymphoma, Eb), a high metastatic spontaneous variant thereof (ESb), and a low metastatic ‘revertant’ from ESb (ESb-M). All three lines expressed tumor-associated transplantation antigens (TATA) which elicited specific T cell-mediated antitumor immune reactions in the host. The strongest host response was elicited upon intradermal inoculation. It could be followed by (a) the infiltration of the locally growing tumor by host cells, such as lymphocytes and macrophages, (b) the establishment of specific systemic antitumor immunity, (c) the generation of immune cells capable of transferring protective antitumor immunity into a normal syngeneic recipient, and (d) the generation of tumor specific cytotoxic T lymphocytes (CTL).
Anti-TATA CTL were used as typing reagents to investigate the stability or variability in the TATA expression by cloned tumor cell lines. Antigenic variability in the TATA expression was seen under various conditions: (a) clone-dependent variation in the sensitivity to anti-TATA CTL lysis upon prolonged growth in tissue culture, (b) qualitative change in the TATA (TATA1 → TATA2) upon successive i.p. transplantation of the parental Eb tumor line and, (c) generation of TATA negative immune escape variants (TATA2 → TATA-) during metastasis formation from a s.c. site.
The relative inefficiency of specific immunization procedures against ESb was found to be due to the effective generation of TATA negative variants by this highly metastatic tumor. The balance between immune control and immune escape could be influenced to the advantage of the host by some means, for instance optimizing the route of antitumor-immune sensitization or by infusion of allogeneic but H-2 identical antitumor-immune T cells. Such immune cells recognized the tumor via minor histocompatibility antigens and thus circumvented the need of TATA recognition. Finally, manipulations at the cell surface of the highly malignant ESb tumor such as those introduced in the ESb-M variant were found to dramatically effect its metastatic potential.
Similar content being viewed by others
References
Fidler IJ, Gersten DM, Hart IR: The biology of cancer invasion and metastasis. Adv Cancer Res (28):149–250, 1978.
Poste G, Fidler IJ: The pathogenesis of cancer metastasis. Nature London (283):139–146, 1980.
Van Den Bossche H: The Host-Invader Interplay. Elsevier/North Holland, Amsterdam, 1980.
Webster RG, Laver WG: Antigenic variation of influenza viruses. In: Kilburne ED (ed) The influenza viruses and influenza. Academic Press, New York, 1975, pp 269–314.
Vickerman K: Antigenic variation in trypanosomes. Nature London (273):613–617, 1978.
Hoeijmakers IHJ, Frasch ACC, Bernards A, Borst P, Cross GAM: Novel expression-linked copies of the genes for variant surface antigens in trypanosomes. Nature London (284):78–80, 1980.
Prehm RT, Main JM: Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst (18):769–778, 1957.
Wahl DV, Chapman WH, Hellström I, Hellström KE: Transplantation immunity to individually unique antigens of chemically induced bladder tumors in mice. Int J Cancer (14):114–121, 1974.
Boon T, Kellerman O: Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc Natl Acad Sci (74):272, 1976.
Boon T, Van Snick J, Van Pel A, Uyttenhove C, Marchand M: Immunogenic variants obtained by mutagenesis of mouse mastocytoma P 815. II. T lymphocyte-mediated cytolysis. J Exp Med (152):1184, 1980.
Sugarbaker EV, Egan JE: Alterations of tumor specific transplantation antigens in metastases. Proc Am Assoc Cancer Res (296):74, 1971.
Faraci RP: In vitro demonstration of altered antigenicity of metastases from a primary methylcholanthrene-induced sarcoma. Surgery (76):469–473, 1974.
Fogel M, Segal S, Gorelik E, Feldman M: Specific cytotoxic lymphocytes against syngeneic tumors are generated in culture in the presence of syngeneic, but not xenogeneic, serum. Int J Cancer (22):329–334, 1978.
Deichman GI, Kluchareva TE: Loss of transplantation antigen in primary Simian virus 40-induced tumors and their metastases. J Natl Cancer Inst (36):647–655, 1966.
Kim U: Metastasizing mammary carcinomas in rats: induction and study of their immunogenicity. Science (167):72–74, 1970.
Hewitt HB: The choice of animal tumors for experimental studies of cancer therapy. Adv Cancer Res (27):149–200, 1978.
Parr I: Response of syngeneic murine lymphomata to immunotherapy in relation to the antigenicity of the tumor. Br J Cancer (26): 174–182, 1972.
Schirrmacher V, Shantz G, Clauer K, Komitowski D, Zimmermann HP, Lohmann-Matthes ML: Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastasis formation in vivo. Int J Cancer (23):233–244, 1979.
Johnson RE, De Vita VT, Chabner BR, Chretien PB, Berard CD, Johnson SK: Patterns of involvement with malignant lymphoma and implications for treatment decision making. Br J Cancer (31), Suppl II:237–241, 1975.
Nowell PC: The clonal evolution of tumor cell populations. Science (194):23–28, 1976.
Schirrmacher V, Bosslet K: Tumor metastases and cellmediated immunity in a model system in DBA/2 mice. X. immunoselection of tumor variants differing in tumor antigen expression and metastatic capacity. Int J Cancer (25):781–788, 1980.
Dzarlieva S, Schirrmacher V, Fusenig N: Cytogenetic changes during tumor progression towards invasion, metastasis and immune escape in the Eb/ESb model system (submitted for publication).
Fogel M, Altevogt P, Schirrmacher V: Metastatic potential severely altered by changes in tumor cell adhesiveness (submitted for publication).
Schwartz R, Schirrmacher V, Bosslet K, Mühlrad P: Glycoconjugates of murine tumor lines with different metastatic capacity. I. Differences in fucose utilization and in glycoprotein patterns (submitted for publication).
Altevogt P, Kurnick JT, Kimura AK, Bosslet K, Schirrmacher V: Different expression of Lyt differentiation antigens and cell surface glycoproteins by a murine T lymphoma line and its high metastatic variant. Eur J Immunol (18):300–307, 1982.
Schirrmacher V, Jacobs W: Tumor metastases and cellmediated immunity in a model system in DBA/2 mice. VIII. Expression and shedding of Fcγ receptors on metastatic tumor cell variants. J Supramol Struct (11):105–111, 1979.
Barz D, Bosslet K, Schirrmacher V: Metastatic tumor cell variants with increased resistance to infection by Semliki-Forest-Virus. J Immunol (127):951–954, 1981.
Davey GC, Currie GA, Alexander P: Spontaneous shedding and antibody induced modulation of histocompatibility antigens on murine lymphomata: correlation with metastatic spread. Br J Cancer (33):9–14, 1976.
Vlodavsky I, Schirrmacher V, Ariav Y, Fuks Z: Lymphoma cell interaction with cultured vascular endothelial cells and with the subendothelial basal lamina: attachment, invasion and morphological appearance (submitted for publication).
Davey GC, Currie GA, Alexander P: Immunity as the predominant factor determining metastasis by murine lymphomas. Br J Cancer (40):590–596, 1979.
Schirrmacher V, Cheingsong-Popov R, Arnheiter H: Hepatocytetumor cell interaction in vitro. I. Conditions for rosette formation and inhibition by anti H-2 antibodies. J Exp Med (151):984–989, 1980.
Lohmann-Matthes M-L, Schleich A, Shantz G, Schirrmacher V: Tumor metastasis and cell-mediated immunity in a model system in DBA/2 mice. VII. Interaction of metastasizing and nonmetastasizing tumors with normal tissue in vitro. J Natl Cancer Inst (64):1413–1425, 1980.
Vlodavsky I, Ariav Y, Fuks Z, Altevogt P, Schirrmacher V: Lymphoma cell mediated degradation of sulfated proteoglycans and of fibronectin in the subendothelial basal lamina: relationship to tumor cell metastasis (submitted for publication).
Waller CA, Schirrmacher V: Quantitative investigation of invasion in a murine paired lymphoma system (in preparation).
Kerbel RS, Twiddy RR, Robertson MD: Induction of a tumor with greatly increased metastatic growth potential by the injection of cells from a low metastatic H-2 heterozygous tumour cell line into an H-2 incompatible parental strain. Int J Cancer (22):583, 1978.
Dennis JW, Donaghue TP, Kerbel RS: Membrane-associated alterations detected in poorly tumorigenic lectinresistant variant sublines of a highly malignant and metastatic murine tumor. J Natl Cancer Inst (66):129–139, 1981.
Kripke ML, Gruys E, Fidler IJ: Metastatic heterogeneity of cells from an ultraviolet light-induced murine fibrosarcoma of recent origin. Cancer Res (38):2962–2967, 1978.
Nicolson GL, Winkelhake JL: Organ specificity of bloodborne metastasis determined by cell adhesion. Nature (255):230, 1975.
Burger MM: The cell surface and metastasis. In: Biology of the cancer cell. Kugler, Amsterdam, 1980, pp 193–208.
Kerbel RS, Dennis JW, Lagarde AE, Frost P: Tumor progression in metastasis: an experimental approach using lection resistant tumor variants. Cancer Metastasis Reviews (2):- , 1982.
Fidler IJ, Gersten DM, Budmen MB: Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. Cancer Res (36):3160, 1976.
Frost P, Kerbel RS: Immunoselection in vitro of a nonmetastatic variant from a highly metastatic tumor. Int J Cancer (27):381–385, 1981.
Poste G: The influence of cell surface properties on the arrest of circulating melanoma cells. In: Hynes RO, Fox CF (eds) Tumor cell surfaces and malignancy. Progr Clin Biol Res (41):737–745, 1980.
De Baetselier P, Gorelik E, Eshhar Z, Ron Y, Katzav S, Feldman M, Segal S: Hybridization between plasmacytoma cells and B lymphocytes confers metastatic properties on a non-metastatic tumor. J Natl Cancer Inst (67):1079–1087, 1981.
Schirrmacher V: Immunogenetic studies on the resistance of mice against highly metastatic DBA/2 tumor cell variants. I. Effect of incompatabilities at H-2 or non-H-2 genes in normal and nude (nu/nu) mice. Invasion Metastasis (1):4–21, 1981.
Schirrmacher V, Bosslet K, Altevogt P, Russman E, Beck L, Fogel M: Microenvironmental influences on tumor-host interactions studied with high and low metastatic tumor lines. Proc. VI. Meeting of EACR, Budapest. Kugler, Amsterdam (in press) 1982.
Schirrmacher V, Hübsch D, Clauer K: Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IX. Radioassay analysis of tumor cell spread from a local site to the blood and liver. In: Cancer Campaign, Grundmann E (ed) Metastatic tumor growth, Vol 4. Gustav Fischer Verlag, pp 147–158.
Bosslet K, Schirrmacher V, Shantz G: Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VI. Similar specificity patterns of protective antitumor immunity in vivo and of cytolytic T cells in vitro. Int J Cancer (24):303–313, 1979.
Eccles SA, Alexander P: Immunologically mediated restraint of latent tumor metastases. Nature (257):52–54. 1975.
Wheelock EF, Weinhold KJ, Levich I: The tumor dormant state. Adv Cancer Res (34):107–140, 1981.
Auerbach R, Morissey LW, Sidky Y: Regional differences in the incidence and growth of mouse tumors following intradermal and subcutaneous inoculation. Cancer Res (38):1739–1744, 1978.
Afzelius LE, Elmage A, Nordgren H: Basal cell carcinoma in the head and neck. The importance of location and histological pictures studied with a new scoring system, predicting recurrences. Acta Pathol Microbiol Scand (88):5–9, 1980.
Bellamy D, Hinsull SM: Influence of lodgement site on the proliferation of metastasis of Walker 256 carcinoma in the rat. Br J Cancer (37):81–85, 1978.
Schirrmacher V: Commentary. Shifts in tumor cell phenotypes induced by signals from the microenvironment: relevance for the immunobiology of cancer metastasis. Immunobiology (157):89–98, 1980.
Folkman J: Tumor angiogenesis and tumor immunity. In: Castro JE (ed) MTP Press, Immunological aspects of cancer Lancaster, England.
Auerbach R, Kubai L, Sidky Y: Angiogenesis induction by tumors, embryonic tissues and lymphocytes. Cancer Res (36):3535–3440, 1976.
Schirrmacher V, Waller CA: Quantitative determination of disseminated tumor cells by 3H-Thymidine incorporation in vitro and by agar colony formation. Cancer Res (42):660–666, 1982.
Schirrmacher V, Bosslet K, Shantz G, Clauer K, Hübsch D: Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between the parental tumor line and its metastasizing variant. Int J Cancer (23):245–252, 1979.
Bertschmann M, Schären B, Lüscher EF: Correlation of in vivo and in vitro immune reactions against intradermally developing P815 mastocytoma in the syngeneic mouse. Immunobiology (156):382–399, 1979.
Hudack SS, McMaster PD: The lymphatic participation in human cutaneous phenomena. A study of the minute lymphatics of the living skin. J Exp Med (57):751, 1933.
Fichtelius KE, Groth O, Liden S: The skin, a first level lymphoid organ? Int Arch Allergy Appl Immunol (37): 607–620, 1970.
Chassoux D, McLennan ICM, Munzo TR: Competition for cytotoxic immune capacity against a syngeneic tumour distributed at two sites. Int J Cancer (19):796, 1977.
Shantz G, Schirrmacher V: Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. III. Induction and specificity of syngeneic cytotoxic T cells. In: Quastel MR (ed) Cell biology and immunology of leukocyte function. Academic Press, New York, 1979, pp 725–736.
Glaser M, Herberman RB: Secondary cell-mediated cytotoxic response to challenge of rats with syngeneic Gross-virus induced lymphomas. J Natl Cancer Inst (56):1211, 1976.
Pilarski LM: Antigen-specific helper T cells are essential for cytotoxic T cell responses to metabolically inactivated stimulator cells. Eur J Immunol (9):454–460, 1979.
Wagner H, Hardt C, Heeg K, Pfizenmaier K, Solbach W, Bartlett R, Stockinger H, Röllinghoff M: T-T cell interactions during cytotoxic T lymphocyte (CTL) responses: T cell derived helper factor (interleukin 2) as a probe to analyse CTL. responsiveness and thymic maturation of CTL progenitors. Immunol (51):215–256, 1980.
Warren HS, Woolnough JA, Denarv CP, Lafferty KJ: Cytotoxic T cell responses to a syngeneic tumor: conditions for primary activation in vitro and biological activity in vivo. In: Müller-Ruchholtz W, Müller-Hermelink HK (eds) Advances in experimental medicine and biology, New York-London, pp 757–761. Vol 14. Plenum Press.
Mills GB, Paetkau V: Generation of cytotoxic lymphocytes to syngeneic tumor by using co-stimulator (interleukin 2). J. Immunol (125):1897–1903, 1980.
Burton RC, Plate JMD: Helper factor(s) augment in vitro induction of tumor-specific immunity. Cell Immunol (58):225–237, 1981.
Kim U, Baumler A, Carruthers C, Bielat K: Immunological escape mechanism in spontaneously metastasizing mammary tumors. Proc Natl Acad Sci (72): 1012–1016, 1975.
Hopkins N, Beamer P, DeLeo AB, Law LW: High-frequency cotransfer of the transformed phenotype and a tumor specific transplantation antigen by DNA from the 3-methylcholanthreneinduced Meth. A sarcoma of BALB/c mice. Proc Natl Acad Sci (78):7555–7559, 1981.
Pratcheva D, DeLeo AB, Ruddle F, Old LJ: Chromosome assignment of the tumor-specific antigen of a 3-methyl-cholanthreneinduced mouse sarcoma. J Exp Med (154):964–977, 1981.
Law LW, Rogers MJ, Appella E: Tumor antigens on neoplasms induced by chemical carcinogens and by DNA- and RNA-containing viruses: properties of the solubilized antigens. Adv Cancer Res (32):201–235, 1980.
Schirrmacher V, Bosslet K: Clonal analysis of expression of tumor-associated transplantation antigens and of metastatic capacity. Cancer Immunol Immunother (13):62–68, 1982.
Schirrmacher V, Altevogt P, Bosslet K: Spontaneous phenotypic shifts from low to high metastatic capacity. Proc NATO Conference ‘Biochemical and Biological Markers of Neoplastic Transformation,’ 1981.
Bosslet K, Ruffmann R, Altevogt P, Schirrmacher V: A rapid method for the isolation of metastasizing tumor cells from internal organs with the help of isopycnic density gradient centrifugation in Percoll. Br J Cancer (44):356–362, 1981.
Bosslet K, Schirrmacher V: Escape of metastasizing clonal tumor cell variants from tumor-specific cytolytic T lymphocytes. J Exp Med (154):557–562, 1981.
Bosslet K, Schirrmacher V: High-frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line (ESb). Int J Cancer (29):195–202, 1982.
Biddison WE, Palmer JC: Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y. Proc Natl Acad Sci (74):329–333, 1977.
Weinhold KJ, Miller DA, Wheelock EF: The tumor dormant state. Comparison of L5178Y cells used to establish dormancy with those that emerge after its termination. J Exp Med (149):745–757, 1979.
Fidler IJ, Kripke ML: Metastasis results from pre-existing variant cells within a malignant tumor. Science (197):893, 1977.
Cairns I: The origin of human cancers. Nature (289):353–357, 1981.
Nevers P, Saedler H: Translocatable genetic elements as agents of gene instability and chromosomal rearrangements. Nature (268):109–115, 1977.
Strathern IN, Herskowitz K: Asymmetry and directionality in production of new cell types during clonal growth: the switching pattern of homothallic yeast. Cell (17):371–381, 1979.
Klein G: The role of gene dosage and genetic transpositions in carcinogenesis. Nature (294):313–318, 1981.
Pays E, Van Meirvenne N, Le Ray D, Steward M: Gene duplication and transposition linked to antigenic variation in Trypanosoma brucei, Proc Natl Acad Sci (78):2673–2677, 1981.
Dennis JW, Donaghue TP, Kerbel RS: An examination of tumor antigen loss in spontaneous metastases. Invasion Metastasis (2):111–125, 1981.
Urban IL, Burton RC, Holland JM, Kripke ML, Schreiber H: Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J Exp Med (155):557–573, 1982.
Boyse EA, Stockert E, Old LJ: Modification of the antigenic structure of the cell membrane by thymusleukemia (TL) antibody. Proc Natl Acad Sci. (58):954, 1967.
Hilgers J, Sonnenberg A, Nusse R: Antigenic modulation of mammary tumor virus envelope antigen on GR thymic lymphoma cells in relation to expression of H-2, TL cell surface antigens and Thy 1. Br J Cancer (42):542, 1980.
Stackpole CW: Modulation of thymus-leukemia antigens on mouse leukemia cells induced by IgG, but not IgM, antibody. J Natl Cancer Inst (64):917, 1980.
Hellström KE, Hellström I: Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol (18):209, 1974.
Broder S, Muul L, Waldmann TA: Suppressor cells in neoplastic disease. J Natl Cancer Inst (61):5–11, 1978.
Naor D: Suppressor cells: permitters and promoters of malignancy? Adv Cancer Res (29):45–125, 1979.
Berendt MI, North NJ: T cell mediated suppression of antitumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med (159):69–80, 1980.
Fidler IJ, Gersten DM, Kripke ML: Influence of immune status on the metastases of three murine fibrosarcomas of different immunogenicities. Cancer Res (39):3816–3821, 1979.
Lindenmann J, Klein PA: Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med (126):93–108, 1967.
Kobayashi H: Viral xenogenization of intact tumor cells. Adv Cancer Res (30):279–299, 1979.
Austin FC, Boone CW: Virus augmentation of the antigenicity of tumor cell extracts. Adv Cancer Res (30):301–345, 1979.
Dennert G, Weiss S, Warner IF: T cells may express multiple activities. Specific allohelp, cytolysis and delayed-type hypersensitivity are expressed by a cloned T cell line. Proc Natl Acad Sci (79):695, 1982.
Burton RC, Warner NL: In vitro induction of tumor specific immunity. IV. Specific adoptive immunotherapy with cytotoxic T cells induced in vitro to plasmacytoma antigens. Cancer Immunol Immunother (2):91–99, 1977.
Kedar E, Schwartzbach M, Hefetz S, Raanan Z: In vitro induction of cell-mediated immunity to murine leukemia cells. V. Adoptive immunotherapy of leukemia in mice with lymphocytes sensitized in vitro to leukemia cells. Cancer Immunol Immunother (4):151–159, 1978.
Cheever MA, Greenberg PD, Feder A: Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro. Cancer Res (41):2658–2663, 1981.
Fernandez-Cruz E, Woda BA, Feldman JD: Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes. J Exp Med (152):823–841, 1980.
Shu S, Steerenberg PA, Hunter JT, Evans CH, Rapp HJ: Adoptive immunity to the guinea pig line 10 hepatoma and the nature of in vitro lymphoid-tumor cell interactions. Cancer Res (41):3499–3506, 1981.
Wiltrout RH, Frost P, Morrison M, Kerbel RS: Immune-mediated arrest and reversal of established visceral metastases in athymic mice. Cancer Res (39):4034–4041, 1979.
Yam LT, Li CY, Crosby WH: Cytochemical identification of monocytes and granulocytes. Am J Clin Pathol (55):283, 1971.
Schirrmacher V, Landolfo S, Zawatzky R, Kirchner H: Immunogenetic studies on the resistance of mice against highly metastatic DBA/2 tumor cell variants. II. Influence of minor histocompatibility antigens on tumor resistance, interferon induction and cytotoxic response. Invasion Metastasis (1):175–194, 1981.
Lake P, Douglas TC: Recognition and genetic control of helper determinants of cell surface antigen Thy 1. Nature (273):220, 1978.
Lake P, Mitchison NA: Regulatory mechanisms in the immune response to cell surface antigens. Cold Spring Harbor Symp Quant Biol (41):589–595, 1977.
Schirrmacher V: Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. V. Transfer of protective immunity with H-2 identical immune T cells from B10.D2 mice. Int J Cancer (24):80–86, 1979.
Berenson IR, Einstein AB, Fefer A: Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirements for T cells. J Immunol (115):234–238, 1975.
Cheever MA, Greenberg PD, Fefer A: Tumor neutralization, immunotherapy and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro. II. Comparison of cells cultured with and without tumor to noncultured immune cells. J Immunol (121):2220–2227, 1978.
Glaser M, Lavrin DH, Herbermann RB: In vivo protection against syngeneic Gross virus-induced lymphoma in rats: comparison with in vitro studies of cell-mediated immunity. J Immunol (116):1507–1511, 1976.
Mihich E: Combined effects of chemotherapy and immunity against leukemia L 1210 in DBA/2 mice. Cancer Res (29):848–854, 1969.
Cifone M, Fidler IJ: Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Acad Sci (78):6949–6952, 1981.
Fischer MS, Cifone MA: Enhanced metastatic potential of murine fibrosarcomas treated in vitro with ultraviolet radiation. Cancer Res (41):3018–3023, 1981.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schirrmacher, V., Fogel, M., Russmann, E. et al. Antigenic variation in cancer metastasis: immune escape versus immune control. Cancer Metast Rev 1, 241–274 (1982). https://doi.org/10.1007/BF00046830
Issue Date:
DOI: https://doi.org/10.1007/BF00046830